MDM2 and prostate carcinoma: A more recent analysis of this trial data indicated that high expression of COX-2 in prostate cancer, in combination with three other genes (ki-67, MDM2 and p16), predicted for an increased risk of developing distant metastases following androgen deprivation therapy and radiotherapy [49].